;

Articles Not Curated - Drug
Last updated: 2025 Jul 18
Total hit(s): 10226
S.No.
1
40329514
Integrating immune library probing with structure-based computational design to develop potent neutralizing nanobodies against emerging SARS-CoV-2 variants.
MAbs
2025 Dec
10
1
2
39720838
Immunogenicity and safety of SARS-CoV-2 recombinant protein vaccine (CHO cell) LYB001 as a heterologous booster following two- or three-dose inactivated COVID-19 vaccine in adults aged >/=18 years: interim results of a randomized, active-controlled, double-blinded, phase 3 trial.
Expert Rev Vaccines
2025 Dec
4.37
1
3
39635731
Nationwide seroprevalence of SARS-CoV-2 Delta variant and five Omicron sublineages in companion cats and dogs in the USA: insights into their role in COVID-19 epidemiology.
Emerg Microbes Infect
2025 Dec
5.84
1
4
40366666
A four-week study on the toxicity of repeated intramuscular administration of plant-based BA-CoV2-0301 vaccine against SARS-CoV-2 in Sprague-Dawley rats.
J Immunotoxicol
2025 Dec
1
5
40376714
Efficacy, immunogenicity, and safety of heterologous boosting with a novel chimera Chinese mRNA (RQ3013) SARS-CoV-2 vaccine: A randomized, double-blind, active-controlled trial.
Hum Vaccin Immunother
2025 Dec
4.7
1
6
39643949
Modeling the potential public health and economic impact of different COVID-19 vaccination strategies with an adapted vaccine in the Kingdom of Saudi Arabia.
Expert Rev Vaccines
2025 Dec
4.37
1
7
40432512
Neutralizing antibody levels as a key factor in determining the immunogenic efficacy of the novel PEDV alpha coronavirus vaccine.
Vet Q
2025 Dec
8.5
1
8
40381203
Safety and immunogenicity of SARS-CoV-2 protein subunit recombinant vaccine (Indovac(R)) in healthy populations aged 18 years and above in Indonesia: A phase I, observer-blind, randomized, controlled study.
Hum Vaccin Immunother
2025 Dec
4.7
1
9
39887328
Willingness to pay for the effect of SARS-CoV-2 antivirals in preventing COVID-19 transmission to others in the Japanese population.
J Med Econ
2025 Dec
1
10
40051347
Limitations of neutralizing antibody titers in COVID-19 vaccine efficacy trials and a call for additional correlates of protection.
Hum Vaccin Immunother
2025 Dec
4.7
1
11
40045463
The characterization of technical design of a virus-like structure (VLS) nanodelivery system as vaccine candidate against SARS-CoV-2 variants.
Hum Vaccin Immunother
2025 Dec
4.7
1
12
40134119
Gaps in vaccine clinical trials in Africa: A mixed scoping review and bibliometric analysis before, during, and post- COVID-19 pandemic.
Hum Vaccin Immunother
2025 Dec
4.7
1
13
39834144
Sustained immunogenicity of bivalent protein COVID-19 vaccine SCTV01C against antigen matched and mismatched variants.
Expert Rev Vaccines
2025 Dec
4.37
1
14
40077853
Characterization of the binding features between SARS-CoV-2 5'-proximal transcripts of genomic RNA and nucleocapsid proteins.
RNA Biol
2025 Dec
1
15
40625176
A second-generation, self-amplifying COVID-19 Vaccine: World's first approval and distribution in the Japanese market with vaccine hesitancy.
Hum Vaccin Immunother
2025 Dec
4.7
1
16
40590376
SARS-CoV-2 RNA-binding protein suppresses extracellular miRNA release.
RNA Biol
2025 Dec
1
17
40613499
A pan-beta-coronavirus vaccine bearing conserved and asymptomatic B- and T-cell epitopes protects against highly pathogenic Delta and highly transmissible Omicron SARS-CoV-2 variants.
Hum Vaccin Immunother
2025 Dec
4.7
1
18
40195167
Safety profile of self-amplifying mRNA SARS-CoV-2 vaccine ARCT-154 in adults: a pooled phase 1/2/3 randomized clinical study.
Expert Rev Vaccines
2025 Dec
4.37
1
19
40028815
Impact of FcRn antagonism on vaccine-induced protective immune responses against viral challenge in COVID-19 and influenza mouse vaccination models.
Hum Vaccin Immunother
2025 Dec
4.7
1
20
40580492
Development of the coronavirus reverse genetic system: Core technology for pathogenesis mechanisms research and vaccine/drug development.
Virulence
2025 Dec
4.81
1
21
40214201
A One Health approach to bovine coronavirus vaccine development, using LSDV as a live virus vector.
Hum Vaccin Immunother
2025 Dec
4.7
1
22
40371698
Natural product sennoside B disrupts liquid-liquid phase separation of SARS-CoV-2 nucleocapsid protein by inhibiting its RNA-binding activity.
J Enzyme Inhib Med Chem
2025 Dec
8.6
1
23
40214651
From Wuhan to Omicron K.P2 strain: A comprehensive review of SARS-CoV-2 phylogeny and public health implications of the latest booster vaccine.
Hum Vaccin Immunother
2025 Dec
4.7
1
24
39865693
Immunogenicity and safety of a COVID-19 DNA vaccine in healthy adults and elderly: A randomized, observer-blind, placebo-controlled phase 2 trial.
Hum Vaccin Immunother
2025 Dec
4.7
1
25
40674170
In vivo antibody diversification targeting a conserved coronavirus epitope.
J Exp Med
2025 Oct 6
10.35
1